Literature DB >> 8968950

Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain.

A Bonnin1, R de Miguel, J G Castro, J A Ramos, J J Fernandez-Ruiz.   

Abstract

The exposure of pregnant rats to delta 9-tetrahydrocannabinol (delta 9-THC), the main psychoactive constituent of Cannabis sativa, during the perinatal period affects the gene expression and the activity of tyrosine hydroxylase (TH) in the brains of their offspring at peripubertal and adult ages. In the present work we explored whether these effects also appear during fetal and early neonatal periods, when TH expression plays an important role in neural development. To this end, the mRNA amounts for TH and the amounts and activity of this enzyme, in addition to catecholamine (CA) contents, were analyzed in the brain of fetuses at different gestational days (GD) and of newborns at two postnatal ages, which had been daily exposed to delta 9-THC or vehicle from d 5 of gestation. Results were as follows. The exposure to delta 9-THC markedly affected the expression of the TH gene in the brain of fetuses at GD 14. Thus, the amounts of its mRNA at this age were higher in delta 9-THC-exposed fetuses than in controls. This corresponded with a marked rise in the amounts of TH protein and in the activity of this enzyme at this age. Normalization was found in these parameters at GD16. However, a marked sexual dimorphism in the response of TH gene to cannabinoid exposure appeared from GD18 and was particularly evident at GD21, when TH-mRNA amounts increased in developing female brains, but decreased in developing male brains exposed to delta 9-THC, effects that were mostly prolonged to early postnatal ages. However, these changes did not correspond always with parallel changes in the amounts and activity of TH and in CA contents, as occurred in GD14, suggesting that delta 9-THC would not be affecting the basal capability to synthesize CAs in TH-containing neurons, but would affect the responsiveness of TH gene. We found only a marked increase in the production of L-3,4-dihydroxyphenylacetic acid, the main intraneuronal dopamine metabolite, in female newborns exposed to delta 9-THC. Collectively, our results support the belief that the perinatal exposure to delta 9-THC affects the expression of the TH gene and, sometimes, the activity of this enzyme in brain catecholaminergic neurons in certain critical periods of fetal and early neonatal brain development. These results support the notion that cannabinoids are able to affect the gene expression of specific key proteins for catecholaminergic development, and that these alterations might be the origin of important long-term neurobehavioral effects caused by perinatal cannabinoid exposure at peripubertal and adult ages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968950     DOI: 10.1007/BF02737066

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

1.  Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

Authors:  M Herkenham; A B Lynn; B R de Costa; E K Richfield
Journal:  Brain Res       Date:  1991-05-03       Impact factor: 3.252

2.  Presence of cannabinoid binding sites in the brain from early postnatal ages.

Authors:  F Rodríguez de Fonseca; J A Ramos; A Bonnin; J J Fernández-Ruiz
Journal:  Neuroreport       Date:  1993-02       Impact factor: 1.837

3.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

4.  Changes in brain dopaminergic indices induced by perinatal exposure to cannabinoids in rats.

Authors:  F Rodriguez de Fonseca; M Cebeira; M L Hernández; J A Ramos; J J Fernández-Ruiz
Journal:  Brain Res Dev Brain Res       Date:  1990-02-01

5.  Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. I. Early ontogeny.

Authors:  L A Specht; V M Pickel; T H Joh; D J Reis
Journal:  J Comp Neurol       Date:  1981-06-20       Impact factor: 3.215

6.  Developmental expression of cannabinoid receptor mRNA.

Authors:  C R McLaughlin; M E Abood
Journal:  Brain Res Dev Brain Res       Date:  1993-11-19

7.  Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids.

Authors:  F Rodríguez de Fonseca; M L Hernández; R de Miguel; J J Fernández-Ruiz; J A Ramos
Journal:  Pharmacol Biochem Behav       Date:  1992-03       Impact factor: 3.533

8.  A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics.

Authors:  B Grima; A Lamouroux; C Boni; J F Julien; F Javoy-Agid; J Mallet
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

9.  Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography.

Authors:  T Nagatsu; K Oka; T Kato
Journal:  J Chromatogr       Date:  1979-07-21

10.  The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development.

Authors:  A Bonnin; R de Miguel; M L Hernández; J A Ramos; J J Fernández-Ruiz
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  17 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 2.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  Neuroimaging of prenatal drug exposure.

Authors:  Diana L Dow-Edwards; Helene Benveniste; Marylou Behnke; Emmalee S Bandstra; Lynn T Singer; Yasmin L Hurd; L R Stanford
Journal:  Neurotoxicol Teratol       Date:  2006 May-Jun       Impact factor: 3.763

4.  Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

Authors:  M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

Review 5.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

6.  delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.

Authors:  M L Hernández; L García-Gil; F Berrendero; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1997-04       Impact factor: 3.444

7.  Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior.

Authors:  Laura R Stroud; George D Papandonatos; Meaghan McCallum; Tessa Kehoe; Amy L Salisbury; Marilyn A Huestis
Journal:  Neurotoxicol Teratol       Date:  2018-09-26       Impact factor: 3.763

Review 8.  New vistas on cannabis use disorder.

Authors:  Miriam Melis; Roberto Frau; Peter W Kalivas; Sade Spencer; Vivian Chioma; Erica Zamberletti; Tiziana Rubino; Daniela Parolaro
Journal:  Neuropharmacology       Date:  2017-03-31       Impact factor: 5.250

Review 9.  Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization.

Authors:  Delphine Psychoyos; K Yaragudri Vinod
Journal:  Drug Test Anal       Date:  2012-08-13       Impact factor: 3.345

10.  Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Delta(9)-tetrahydrocannabinol.

Authors:  Alberto Pérez-Rosado; María Gómez; Jorge Manzanares; José A Ramos; Javier Fernández-Ruiz
Journal:  Neurotox Res       Date:  2002-05       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.